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Abstract
Background: Early age at infection with hepatitis B virus (HBV) increases the risk of chronic HBV infection. In addition
early age at infection may further increase the risk of persistent viral replication beyond its effect on chronicity. The effects
of perinatal and early postnatal transmission on the risk of prolonged hepatitis B e antigenaemia in children with chronic
HBV infection are not well documented in Africa. We examine these associations using maternal HBV sero-status and the
number of HBV-positive older siblings as proxy measures for perinatal and early postnatal transmission, respectively.
Methods: Hepatitis B e antigen (HBeAg)-positive mothers were identified in six population-based HBV sero-surveys
conducted in The Gambia between 1986 and 1990. For every HBeAg-positive mother, a hepatitis B surface antigen
(HBsAg)-positive HBeAg-negative mother and HBsAg-negative mother were randomly selected from the population
surveyed. These mothers and their family members were tested for HBV sero-markers in a subsequent survey
conducted between 1991 and 1993.
Results: Thirty-eight HBeAg positive mothers and the same number of HBsAg-positive HBeAg-negative mothers
and HBsAg-negative mothers participated in the study. Sixty-nine percent of their children also participated. There was
a non-significant positive association between HBeAg prevalence in children and the number of HBeAg-positive older
siblings (64.1%, 69.2% and 83.3% in children with 0, 1 and ≥2 HBeAg-positive older siblings, respectively). After adjusting
for confounders, having an HBeAg-positive mother was a risk factor for HBeAg positivity in children carrying HBsAg
(adjusted OR 4.5, 95% CI: 1.0-19.5, p = 0.04), whilst the number of HBeAg-positive older siblings was not.
Conclusions: Maternal HBeAg was associated with positive HBeAg in children with chronic HBV infection. This
suggests that interrupting mother-to-infant transmission in sub-Saharan Africa might help reduce the burden of liver
disease. A timely dose of HBV vaccine within 24 hours of birth, as recommended by WHO, should be implemented in
sub-Saharan Africa.
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Background
Chronic infection with the hepatitis B virus (HBV) is a
cause of hepatocellular carcinoma (HCC) [1]. The risk of
chronic infection after exposure to HBV depends on the
age at infection; infection becomes chronic in 80–90%,
20–30%, <10%, and <5% of individuals who are infected
during perinatal period, early childhood, adolescence
and adulthood, respectively [2]. Early HBV infection is
therefore associated with a higher risk of HCC through
the increased risk of chronic infection [3]. However, be-
yond its effect of increasing the chance of becoming a
chronic carrier, early age at HBV infection may further
increase the risk of persistent viral replication, which
ultimately leads to HCC [4]. The immaturity of the host
immune system in neonates and toddlers has been sug-
gested as a mechanism of prolonged e antigenaemia [5].
A recent systematic review of observational studies [6]
found a positive association between having a mother
positive for HBV sero-marker (a proxy for perinatal
mother-to-infant transmission) and prolonged hepatitis
B e antigenaemia (an indicator of high viral replication)
amongst children with chronic HBV infection. There
was also a positive association between maternal sero-
positivity and paediatric HCC. These findings suggest
that HBV infection in early life through perinatal
maternal transmission might increase the risk of HCC
by maintaining a high viral replication.
However, the scope of the review was limited since: 1)
most of the studies included were from East Asia where
mother-to-infant transmission is frequent [7], and 2) none
of the studies examined the infectious status of older
siblings, who are known to be a major source of HBV in-
fection in many parts of the world including sub-Saharan
Africa (sSA) [5,8,9]. Thus, the contribution of sibling-
to-sibling HBV transmission during early childhood to the
prolonged viral replication remains to be determined.
In this study we examined the association between age
at HBV infection and the presence of hepatitis B e antigen
(HBeAg) in The Gambia, West Africa, using maternal
HBV sero-status and number of HBV-positive older
siblings as a proxy for perinatal and early postnatal
transmission, respectively. The analysis was restricted
to study participants with positive hepatitis B surface
antigen (HBsAg), because our aim was to identify the
effect of age at infection (or mode of transmission) on
the risk of hepatitis B e antigenaemia, beyond its effect
of increasing the risk of chronic HBV infection [6].
Methods
Setting
A nation-wide hepatitis B vaccination trial was initiated
in The Gambia in 1986 and by 1990 countrywide cover-
age was achieved [10]. In parallel, six population-based
sero-surveys for HBV infection were conducted in The
Gambia between 1986 and 1990 to assess immunological
response to the vaccine and to determine risk factors for
HBV transmission [9-11]. These surveys obtained sera
from both children and their mothers and tested for the
presence of HBsAg in all the samples, and those that
tested positive for HBsAg were further tested for HBeAg.
In total, 53 HBeAg-positive mothers were identified
from these studies (Figure 1).
On the basis of the HBV sero-status determined at
these surveys, all HBeAg-positive mothers were invited
to participate in “HBeAg Study”. The same numbers of
HBsAg-positive HBeAg-negative mothers and HBsAg-
negative mothers were randomly selected from the data-
bases used in these surveys. Between 1991 and 1993, these
mothers (i.e., index women) and their family members
were bled for HBV markers to determine the effect of
familial HBV sero-markers on presence of HBeAg.
After consent was obtained, the index women were
bled and interviewed to collect demographic information
on dead and living family members. Index women were
bled twice, the first bleeding occurred between 1986 and
1990 and the second at the time of the HBeAg Study
(1991–1993). We used the serological status recorded in
the first survey as a proxy for serological status at birth
of their children.
Family members of the index woman (excluding half
siblings), were contacted and if they agreed to participate
in the study, were bled for HBV serology. All sera were
assayed for HBsAg by reverse passive haemagglutination
(Wellcotest, Murex Diagnostics, UK). HBeAg was tested
by radioimmunoassay (Sorin, Biomedica, Italy) only when
sera were HBsAg-positive. The study was approved by the
Gambia Government/MRC (Medical Research Council)
Joint Ethical Committee and the ethics committee at IARC
(International Agency for Research on Cancer), France.
Data analysis
The association between maternal HBV markers (HBsAg,
HBeAg) and e antigenaemia was examined in successive
generations: mothers of index women (1st generation) and
index women (2nd generation); and index women (2nd
generation) and their children (3rd generation). The effect
of the number of older siblings positive for HBsAg or
HBeAg was evaluated in index women (2nd generation)
and their children (3rd generation).
Logistic regression was used to estimate adjusted odds
ratios for the associations between familial HBV sero-
status (maternal sero-status and number of elder siblings
positive for HBV markers) and e antigenaemia in index
women (2nd generation). In the children of index women
(3rd generation), adjusted odds ratios for the same asso-
ciations were estimated using generalised estimating
equations with an exchangeable correlation structure to
account for household clustering (the previous analysis
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did not account for household clustering because none
of index women shared the same mother). A linear test
for trend was used to assess the statistical significance of
the number of elder siblings positive for HBeAg and the
number positive for HBsAg.
A minimally sufficient set of a priori confounders of
the association between each of the familial sero-markers
and e antigenaemia was identified from a causal diagram
(Figure 2) by applying the backdoor test [12]. The set of
confounders was the same for each familial sero-marker,
and consisted of: year of birth, total sibship size (as a
proxy for parental socioeconomic status), and the other
familial HBV sero-status measures. To estimate the effect
of maternal HBeAg, the set of confounders was: year of
birth, total sibship size, maternal HBsAg, number of older
siblings with positive HBsAg, and number of older siblings
with positive HBeAg. And to estimate the effect of the
number of older siblings with positive HBeAg, the set of
confounders was: year of birth, total sibship size, maternal
HBsAg, maternal HBeAg, and number of older siblings
with positive HBsAg. A history of hepatitis B vaccination
in children of index women was not considered a con-
founder for the association of maternal HBV sero-status
with e antigenaemia in children, because hepatitis B vac-
cine was given irrespective of maternal HBV sero-status
[10,13]. The mothers of index women (1st generation)
were all negative for HBeAg and only one index woman
had an HBeAg-positive older sibling. These variables
Figure 1 Flow chart of study participants in the HBeAg Study, The Gambia, 1991–1993. 1Origins of HBeAg-positive mothers are the
following: GHIS group 1 (n = 18), GHIS group 3 (n = 17), Arthropod study (n = 6), Manduar sero-survey (n = 4), Farafenni sero-survey (n = 6),
and Banjul sero-survey (n = 2).
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were therefore omitted from multivariable models of e-
antigenaemia in index women (2nd generation).
Results
Participation
Out of 53 HBeAg-positive index women (2nd generation)
in the database, 38 (71.7%) were traced and agreed to
participate in the study. The rate of refusal among
HBeAg-negative index women was not recorded. More
than 65% of the mothers (1st generation) and children
(3rd generation) of index women participated in the
study, but participation was less than 35% among older
siblings of index women (Figure 1).
Index women (2nd generation)
The characteristics of 38 HBsAg-positive HBeAg-positive
index women and 38 HBsAg-positive HBeAg-negative
index women are presented in Table 1. The median age in
index women was 25.0 years (interquartile range: 23–30)
for HBeAg-positive and 26.5 years (interquartile range:
22–30) for HBeAg-negative index women (Wilcoxon
rank-sum test: p = 0.75). The associations between familial
HBV sero-status and HBeAg positivity in HBsAg-positive
index women are presented in Table 2. The proportion
of index women who have HBsAg-positive mothers was
higher in HBeAg-positive index women (16.7%, 4/24)
than in HBsAg-positive HBeAg-negative index women
(7.7%, 2/26), although the difference was not statistically
significant (p = 0.33). None of the HBsAg-positive mothers
of index women (1st generation) were HBeAg-positive. The
proportion of index women with HBsAg-positive older sib-
lings was similar in HBeAg-positive index women (15.4%,
4/26) and HBsAg-positive HBeAg-negative index women
(17.2%, 5/29). After adjusting for confounding factors,
there was no evidence for an association between HBeAg
positivity in index women and either maternal HBsAg
(OR 1.2, 95% CI: 0.1-23.2, p = 0.89) or having an HBsAg-
positive older sibling (OR 0.9, 95% CI: 0.2-5.5, p = 0.92).
Children of index women (3rd generation)
In total, 96, 102 and 101 children of HBeAg-positive,
HBsAg-positive and HBeAg-negative, and HBsAg-negative
index women participated, respectively. Of whom, 38
(39.6%), 14 (13.7%) and 6 (5.9%) tested positive for HBsAg,
respectively (p < 0.001, Figure 1). The characteristics of
these HBsAg-positive children (n = 58) by maternal HBV
marker are presented in Table 3. The median age was
similar in the three groups. However, HBsAg-positive
Figure 2 Causal diagram for the effect of familial HBV marker on hepatitis B e antigenaemia in the HBeAg Study, The Gambia,
1991–1993. Maternal HBV sero-marker and number of older siblings with positive HBV sero-marker are proxies for perinatal and early postnatal HBV
transmission, respectively. Early age at HBV infection is associated with positive HBeAg through increasing the risk of chronic HBV infection. The hypothesis
of this analysis is in addition to this effect, early age at infection further increases the risk of hepatitis B e antigenaemia (presented as a dashed arrow).
The variables which were not measured are surrounded by dashed lines, and the exposure and outcome variables of interest are surrounded by lines
in bold-type. SES denotes socio-economic status.
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children with HBeAg-positive mothers were more likely
to be female, HBV vaccinated and to have three or
fewer siblings than HBsAg-positive children born to
HBeAg-negative mothers.
The associations between familial HBV sero-status and
HBeAg positivity in HBsAg-positive children (3rd gener-
ation) are presented in Table 4. There was a non-significant
trend that HBeAg prevalence in children increased with
increasing number of HBeAg-positive older siblings (64.1%,
69.2% and 83.3% in children with 0, 1, and ≥2 HBeAg-
positive older siblings, respectively), but there was no trend
after adjusting for confounding. In contrast, the presence
of maternal HBeAg was a risk factor for HBeAg positivity
after adjusting for confounding (adjusted OR 4.5, 95% CI:
1.0-19.5, p = 0.04). The prevalence of e antigenaemia was
similar between vaccinated (70.0%, 7/10) and unvaccinated
(66.7%, 32/48, p = 0.84) children.
Discussion
We examined the effect of HBV sero-markers in mothers
and older siblings on hepatitis B e antigenaemia in chil-
dren carrying HBsAg (3rd generation). We found that e
antigenaemia in children was positively associated with
maternal HBeAg but not with maternal HBsAg. Likewise,
the prevalence of e antigenaemia in children was higher if
older siblings were HBeAg positive, although this result
was not statistically significant. These relationships imply
that the early establishment of chronic HBV infection
through perinatal transmission from infectious mothers,
as well as early postnatal transmission from infectious
older siblings is associated with presence of HBeAg. In
addition, this is consistent with the observation that
positive HBeAg confers greater infectivity than HBsAg
positivity alone. For example, the risk of perinatal
transmission is 10–17% in HBsAg-positive mothers
Table 2 Risk factors for HBeAg positivity in HBsAg-positive index women (2nd generation)
Variables HBsAg (+) HBeAg (+)
index women (n = 38)
HBsAg (+) HBeAg (−)
index women (n = 38)
Crude odds ratios Adjusted odds ratios1
No % No % OR 95% CI P OR 95% CI P
Maternal HBsAg (1st generation)
Negative 20 83.3 24 92.3 1.0 0.3 1.0 0.9
Positive 4 16.7 2 7.7 2.4 0.4-14.5 1.2 0.1-23.2
Maternal HBeAg (1st generation)
Negative 24 100 26 100 1.0 1.0
Positive 0 0 0 0 N/A N/A
No. of older siblings with positive HBsAg
0 22 84.6 24 82.8 1.0 0.9 1.0 0.9
1-2 4 15.4 5 17.2 0.9 0.2-3.7 0.9 0.2-5.5
No. of older siblings with positive HBeAg
0 25 96.2 29 100 1.0 1.0
1 1 3.8 0 0 N/A N/A
1Model included maternal HBsAg, number of older siblings with HBsAg, year of birth, and total sibship size.
Table 1 Characteristics of HBsAg-positive HBeAg-positive index women and HBsAg-positive HBeAg-negative index
women (2nd generation)
Variables HBsAg (+) HBeAg (+) index women (n = 38) HBsAg (+) HBeAg (−) index women (n = 38)
No % No %
Age group 17-20 6 15.8 7 18.4
21-30 25 65.8 22 57.9
31-45 7 18.4 9 23.7
Year of birth 1948-1960 6 15.8 8 21.0
1961-1970 27 71.0 24 63.2
1971-1974 5 13.2 6 15.8
Total sibship size 1-4 16 42.1 8 21.0
5-6 12 31.6 15 39.5
≥7 10 26.3 15 39.5
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without HBeAg and 63–67% in HBeAg positive mothers
in sSA [14,15]. Indeed, in the current study, we observed
that prevalence of HBsAg in children with HBeAg-positive
mothers was significantly higher than that in children
with HBsAg-positive but HBeAg-negative mothers (40%
versus 15%).
The associations of familial HBeAg with e antigenaemia
in index women (2nd generation) could not be confirmed
because all of the mothers of index women (1st generation)
tested negative for HBeAg and only one older sibling
of index women tested positive for HBeAg. The low
prevalence of HBeAg in the mothers and older siblings of
index women was expected since HBeAg is lost over time.
In The Gambia, 85% of children who established chronic
HBV infection during early childhood had lost HBeAg by
the second decade of life [16]. This makes it difficult to
investigate the effect of familial HBeAg status in adults.
A strength of our study was that we could assess the
effect of familial HBV sero-status, rather than a family
history of HBV infection. The latter is inaccurate because
the absence of such a history does not necessarily indicate
that the family member was sero-negative for HBsAg [6].
Table 3 Characteristics of HBsAg-positive children (3rd generation) according to maternal HBV sero-status
Variables HBsAg(+) HBeAg(+) mother (n = 38) HBsAg(+) HBeAg(−) mother (n = 14) HBsAg(−) mother (n = 6)
No. % No. % No. %
Sex Male 12 31.6 8 57.1 5 83.3
Female 26 68.4 6 42.9 1 16.7
Age group 0-5 15 39.5 2 14.3 3 50.0
6-10 16 42.1 9 64.3 2 33.3
≥11 7 18.4 3 21.4 1 16.7
Year of birth 1973-1980 5 13.2 3 21.4 1 16.7
1981-1985 18 47.4 9 64.3 3 50.0
1986-1991 15 39.4 2 14.3 2 33.3
Total sibship size 1-3 10 26.3 1 7.1 1 16.7
4-5 9 23.7 7 50.0 5 83.3
6-7 19 50.0 6 42.9 0 0.0
HBV vaccination No 28 73.7 14 100 6 100
Yes 10 26.3 0 0.0 0 0.0
Table 4 Risk factors for HBeAg positivity in HBsAg-positive children (3rd generation)
Variables Prevalence
of HBeAg (+)
Crude odds ratios Adjusted odds ratios2,3
OR 95% CI P OR 95% CI P
Maternal HBsAg (2nd generation)
Negative 83.3% (5/6) 1.0 0.5 1.0 0.5
Positive 65.4% (34/52) 0.4 0.1-4.2 0.4 0.1-5.3
Maternal HBeAg (2nd generation)
Negative 60.0% (12/20) 1.0 0.5 1.0 0.04
Positive 71.1% (27/38) 1.6 0.4-6.1 4.5 1.0-19.5
No of older siblings with positive HBsAg
0 65.6% (21/32) 1.0 0.71 1.0 0.91
1 66.7% (10/15) 1.0 0.3-3.8 1.1 0.2-7.2
≥2 72.7% (8/11) 1.4 0.3-6.4 1.2 0.0-47.5
No. of older siblings with positive HBeAg
0 64.1% (25/39) 1.0 0.41 1.0 0.81
1 69.2% (9/13) 1.3 0.3-4.9 1.1 0.3-4.9
≥2 83.3% (5/6) 2.8 0.3-27.7 2.0 0.1-42.7
1Linear test for trend.
2Model included maternal HBsAg, maternal HBeAg, number of older siblings with HBsAg, number of older siblings with HBeAg, year of birth, and total sibship size.
3Wald test from generalised estimating equations.
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Second, we could control for the HBV markers of older
siblings when assessing the association of maternal HBV
sero-status with HBeAg positivity. And similarly the asso-
ciation between siblings’ sero-status and HBeAg positivity
was adjusted for maternal HBV markers. In other studies
this has not been possible [4,17-22]. The mutual adjust-
ment with siblings’ sero-markers was particularly relevant
in The Gambia, where sibling-to-sibling transmission
during early childhood is the most frequent route [8,9].
After adjustment the OR for the association between
maternal HBeAg and e antigenaemia in children increased
whilst the ORs for the number of HBeAg-positive older
siblings decreased. This suggests that perinatal maternal
transmission might be more important in determining the
risk of persistent viral replication than early horizontal
transmission from older siblings in The Gambia. This is
consistent with the hypothesis that earlier age at HBV
infection is associated with higher risk of e antigenaemia.
Two African case–control studies have investigated
the association between age at HBV infection and HCC,
ultimate sequelae of chronic HBV infection. Larouze et al.,
found that the prevalence of maternal HBsAg was higher
in HCC cases (71.4%, 20/28) than in healthy controls
(14.3%, 4/28, P < 0.0001) while the prevalence of HBsAg in
siblings was similar in cases (9.6%, 7/73) and controls
(14%, 8/58) [3]. Ryder et al., studied the association be-
tween birth order and HCC, and found strong evidence
that higher birth order, and hence earlier age at infection,
is associated with higher HCC risk (P < 0.005) [23]. In the
absence of immunisation, children with low birth order are
exposed to HBV after they start schooling, whilst children
with high birth order are infected much earlier by their
older siblings who got the infection outside the household
[24]. However, because individuals negative for HBsAg
were included in both studies, the associations might be
due to an increased risk of chronic HBV infection related
with early age at infection. The results of these studies are
therefore not directly comparable to our findings.
The study has several limitations. Firstly, the sample
size was small, and the associations were therefore poorly
estimated. Secondly, many family members of the index
women did not participate in the HBeAg study, and
this might have led to selection bias. Thirdly, important
confounding variables might have been omitted, in par-
ticular viral genotype. In Taiwan where genotype B (80%)
and C (20%) predominate, genotype C was found to be
associated with delayed HBeAg seroconversion [25] and
also with more frequent mother-to-infant transmission
[4]. In The Gambia, genotype E is predominant (75–95%)
followed by A [26-28]. Although there are only few African
studies relating viral genotypes to clinical outcomes
[29], preliminary data from other West African countries
(Nigeria, Cameroon and Mali) suggest that HBeAg
prevalence might be higher in subjects infected with
genotype E (89.8%, 35/39) than in those with genotype
A (33.3%, 2/6) [30].
HBV vaccination programmes in Africa and Asia have
been successful in preventing postnatal horizontal trans-
mission of HBV, thereby reducing the prevalence of
chronic HBV infection [31,32]. However, they have had
a limited impact on perinatal mother-to-infant transmis-
sion, especially when the mothers are HBeAg-positive or
highly viraemic [31,33]. In East Asia, where perinatal
maternal transmission is common, HBV vaccine is fre-
quently given within 24 hours of delivery (i.e. timely birth
dose) [34,35]. By contrast a timely birth dose of HBV
vaccine is rarely administered in Africa because logistical
challenges seem to outweigh its potential impact due to
the relatively low frequency of mother-to-infant transmis-
sion [36]. Despite a high coverage of hepatitis B vaccine,
only six countries in sSA are undertaking the birth dose
by the end of 2012 and The Gambia is one of them [37].
However, in two villages in rural Gambia where HBV
vaccine efficacy was evaluated [31], only 2.8% (63/2173)
of children who were vaccinated against HBV between
1984 and 2007 were given a dose within 24 hours of
birth (unpublished data). This might be because in The
Gambia, most children are born at home, and are usu-
ally not taken away from home in the first week [38].
Conclusion
Our study suggests that the risk of prolonged e antige-
naemia, an important predictor of HCC [39], is higher in
individuals who perinatally established chronic infection
through infectious mothers than in those infected with
HBV by horizontal transmission. This implies that inter-
rupting mother-to-infant transmission in sub-Saharan
Africa might help reduce the burden of liver disease. A
timely dose of HBV vaccine within 24 hours of birth, as
recommended by WHO [40], needs to be implemented
in sub-Saharan Africa.
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